Erstree ⁢Debuts ‘Super Breath Renomase’: An⁢ Italian Enzyme‍ for Digestive Health

GC Green Cross Wellbeing’s health functional⁢ food distributor, Erstree, has introduced Super Breath Renomase, a new digestive enzyme ⁤supplement featuring‍ enzymes sourced from organic Italian grains.

The supplement utilizes fermented Italian grains and is designed to aid in gluten degradation, supporting both digestive health and healthy blood sugar levels. Super Breath Renomase ⁢combines premium European grains⁢ with advanced enzyme technology, featuring ‘Eleedel Paro,’ a grain raw material with European Union DOP (Protected Designation of Origin) certification.The product boasts 1 million units of enzyme activity, manufactured using technology for gluten degradation.

Furthermore, the formula incorporates two patented lactic acid bacteria strains developed by the GC green Cross Wellness Research Institute. These strains are intended to foster the growth of beneficial gut bacteria, improve digestive function, and help manage post-meal blood sugar spikes.

“Super Breath Renomase was developed with ‍a focus on the ⁢digestive well-being of today’s individuals,” a company spokesperson stated. “We believe it will ⁣be a valuable addition to promoting ⁤healthier eating habits.”

Dong-A Pharmaceutical Revamps ⁤Packaging⁣ for Ichinon Cream

Dong-A Pharmaceutical has announced a ⁣packaging refresh for its Ichinon Cream, a topical treatment for dry, itchy⁣ skin.

The updated packaging ⁤aims to⁣ improve ⁣consumer understanding by highlighting the product’s key features. The front of the package now prominently displays the phrase ‍”Itching of skin dryness” to ⁢clearly indicate the cream’s primary use. ⁤ The packaging also ⁣emphasizes that the cream is steroid-free.

The side panel uses visual cues to⁢ represent key ingredients: heparinoids, tocopherol acetate, diphenhydramine, and allantoin.

Ichinon Cream, launched in 2019, contains these ingredients to alleviate itching and maintain skin hydration. The ‍heparinoids provide moisturizing benefits for dry skin, and the absence of steroids makes it ‍suitable ⁢for a ‍wider range of users.

A Dong-A Pharmaceutical representative commented, “This packaging⁢ update ⁢focuses on clearly communicating the product’s benefits to consumers. We hope Ichinon Cream will help individuals maintain⁢ well-hydrated⁣ skin, especially during seasonal transitions.”

Sillagen Expands Clinical Trials for BAL0891 in Acute Myeloid Leukemia

sillagen is broadening its clinical trial ⁤program for the anticancer drug BAL0891 to include acute myeloid leukemia (AML). The trials will be conducted at five ⁣prominent institutions, including the MD Anderson Cancer Center, Yale Cancer Center, and Montefiore Einstein Cancer Center, along with one institution in Korea.

BAL0891 is a first-in-class drug that inhibits both Thrreonetyrosinekinase (TTK) and PLK1 (Polo-Like Kinase 1).

Sillagen has⁣ submitted an‍ Investigational‍ New Drug (IND) request to ⁤the U.S. food and Drug Management (FDA) seeking approval to expand BAL0891’s indications to include AML.

BAL0891’s mechanism of action involves disrupting cancer ⁣cell division by inhibiting two kinases essential to the process, ultimately leading to cell death.

Preclinical studies have demonstrated BAL0891’s ability to inhibit tumor growth and improve survival rates in AML models, particularly when used in ‍combination with BCL-2 inhibitors. These promising results led major cancer centers like MD Anderson and Yale to participate in the clinical ⁣trials.

The Phase 1 clinical trial⁤ will‍ assess the safety of BAL0891 as a monotherapy in patients with ⁢relapsed or refractory AML, determining the maximum tolerated dose (MTD) and ⁣recommended Phase⁢ 2 dose ⁣(RP2D).

“Acute myeloid leukemia is a challenging⁣ blood ⁤cancer with ⁤high recurrence rates and poor prognoses,” ‍a Sillagen representative stated.⁣ “We‍ believe BAL0891’s dual-inhibition mechanism⁢ has the potential to‍ overcome the limitations of existing treatments. We are committed to advancing its research and growth.”

DEX & VX Licenses Worldwide Coronavirus Treatment Technology

DX & VX⁢ has entered into an agreement with Luka AI to license technology for a next-generation antiviral treatment platform.

The licensed technology offers a⁢ universal therapeutic approach to ⁣coronaviruses and their variants, including potentially⁢ perilous viruses like ‍SARS and MERS, and addresses the threat of future pandemics.

This acquisition‍ provides DX &⁣ VX with a treatment technology for a broad range of viral diseases, including emerging threats like Disease X (unknown disease).

The lead peptide treatments developed by Luka are designed to recognize and target small viruses, such as coronaviruses. They bind to the lipid⁢ surface of the virus and disrupt its structure, acting as an ⁤antiviral agent.

As these treatments target structures smaller than 200 nanometers, they are expected to have minimal side effects or toxicity ⁣to normal cells. The technology also offers the advantage of rapidly adapting to viral mutations ⁢and is ⁣potentially applicable to‍ viruses‍ such as Zika, Ebola, Dengue, and Marburg.

Kwon ‍Kyu-chan, CEO of DX & VX, stated, “We are ⁤pleased to introduce Luka’s innovative antiviral treatment⁢ technology. This agreement strengthens our ability to ⁤prepare ⁢for ⁤future health crises, including ⁣Disease X.”

Cho Nam-joon, CEO of Luka Technology, added, “The emergence of Disease X is a real possibility, and preparedness requires collaboration between companies, academia, and governments.”